LPAR1 and glomerulosclerosis: However, the administration of AM095, an LPAR1 inhibitor, attenuated the inflammatory response in STZ-induced diabetic mice, leading to a reduction in kidney weight, alleviation of albuminuria, and amelioration of glomerulosclerosis, thereby improving DN [13].